Kathleen Moore, MD, MS, FASCO, Debra Richardson, MD - Current and Future Treatment of Platinum-Resistant Ovarian Cancer With ADCs: Implications of Targeting CDH6

episode

CME in Minutes: Education in Oncology & Hematology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-24-2026 9AM EDT 5 min · 24 Sep 2026 · NPR News Now

9AM ET 09/24/2026 Newscast 3 min · 24 Sep 2026 · Fox News Hourly Update

The Critic Who Finally Came Around | Jeanine Pt. 5 6 min · 24 Sep 2026 · The Best 5 Minute Wine Podcast

Ambitious But Lazy? Use This CIA Trick to Beat 99% of People 19 min · 24 Sep 2026 · EverydaySpy Podcast

Postpartum Fitness & My Boob Job… 1h 15m · 24 Sep 2026 · Pursuit of Wellness

326. Rethinks: The Secrets to Getting the Information You Need from AI 28 min · 24 Sep 2026 · Think Fast Talk Smart: Communication Techniques

Report any issue

Source

Recorded30 Sep 2025

Publisherc.answersincme.com ↗

Handlerec:10322488

Show notes

Please visit answersincme.com/YMJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in gynecologic oncology discuss the evolving clinical roles of antibody–drug conjugates (ADCs) in ovarian cancer, focusing on CDH6-targeted ADCs. Upon completion of this activity, participants should be better able to: Identify the rationale for using antibody–drug conjugates (ADCs) in the treatment of platinum-resistant ovarian cancer (PROC); Evaluate the evidence for emerging CDH6-targeted ADCs in the treatment of patients with PROC; Outline expected clinical implications of the evidence for emerging CDH6-targeted ADCs in the treatment of PROC.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in